Allogene Therapeutics (ALLO) Q1 2026 Earnings
ALLO·Reported May 13, 2026·After market close
Diluted EPS came in at $-0.18 (+35.7% YoY), beat the $-0.19 consensus by $0.01.
Diluted EPS
$-0.18beat by $0.01
Consensus: $-0.19
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Allogene Therapeutics's Q1 2026 earnings report.
Allogene Therapeutics (ALLO) reported Q1 2026 earnings on May 13, 2026 after market close.
Allogene Therapeutics reported diluted EPS of $-0.18 for Q1 2026.
EPS beat the consensus estimate of $-0.19 by $0.01.
Compared to the same quarter a year prior, diluted EPS grew 35.7% from $-0.28.
You can read the 8-K earnings release (0001628280-26-034583) and the 10-Q periodic report (0001628280-26-034585) directly on SEC EDGAR. The filing index links above go to sec.gov.